Cytisinicline

Name: Cytisinicline in Smoking cessation: Mechanism of action
Published: 2026-09-14T15:39:06-04:00

Smoking cessation

Manufacturer: Achieve Life Sciences
Regulatory submission: NDA resubmission planned for the fourth quarter of 2026
Launch: Anticipated after potential approval in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Mechanism of action

2 evidence topics · 2 sources

Mechanism of action

“Cytisinicline is a novel smoking cessation medication that acts as a partial agonist at the α4β2 nicotinic acetylcholine receptor, similar to varenicline.” (opens the source at this quote in a new tab)

Nicotine-receptor binding and withdrawal

“Cytisinicline binds to the same receptors as nicotine to reduce both withdrawal symptoms and satisfaction associated with smoking and vaping.” (opens the source at this quote in a new tab)